Overview of approaches for screening for ubiquitin ligase inhibitors

Methods in Enzymology

Volumn 399, Issue , 2005, Pages 654-663

  Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGASE INHIBITOR; UBIQUITIN PROTEIN LIGASE;

CANCER INHIBITION; CATALYSIS; CELL CYCLE; CELL FUNCTION; CHEMOLUMINESCENCE; ENZYME ACTIVATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; LABORATORY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SCINTILLATION; SCREENING; UBIQUITINATION;

DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT ANTIBODY TECHNIQUE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EUKARYOTA;

EID: 28844501665     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)99043-5     Document Type: Review

References (12)

1. Boisclair M.D., McClure C., Josiah S., Glass S., Bottomley S., Kamerkar S., and Hemmila I. Development of a ubiquitin transfer assay for high throughput screening by fluorescence resonance energy transfer J. Biomol. Screen. 5 2000 319 328
2. Ciechanover A. The ubiquitin-proteasome pathway: On protein death and cell life EMBO J. 17 1998 7151 7160
3. Davydov I.V., Woods D., Safiran Y.J., Oberoi P., Fearnhead H.O., Fang S., Jensen J.P., Weissman A.M., Kenten J.H., and Vousden K.H. Assay for ubiquitin ligase activity: High-throughput screen for inhibitors of HDM2 J. Biomol. Screen. 9 2004 695 703
4. Hong C.A., Swearingen E., Mallari R., Gao X., Cao Z., North A., Young S.W., and Huang S.G. Development of a high throughput time-resolved fluorescence resonance energy transfer assay for TRAF6 ubiquitin polymerization Assay Drug Dev. Technol. 1 2003 175 180
5. Pray T.R., Parlati F., Huang J., Wong B.R., Payan D.G., Bennett M.K., Issakani S.D., Molineaux S., and Demo S.D. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets Drug Resist. Update 5 2002 249 258
6. Rolfe M., Beer-Romero P., Glass S., Eckstein J., Berdo I., Theodoras A., Pagano M., and Draetta G. Reconstitution of p53-ubiquitinylation reactions from purified components: The role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP) Proc. Natl. Acad. Sci. USA 92 1995 3264 3268
7. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy Cancer Biol. Therapy 2 2003 623 629
8. Swaroop M., Wang Y., Miller P., Duan H., Jatkoe T., Madore S., and Sun Y. Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: Chip profiling implicates its role in cell cycle regulation Oncogene 19 2000 2855 2866
9. Teodoro J.G., Heilman D.W., Parker A.E., and Green M.R. The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53 Genes Dev. 18 2004 1952 1957
10. Treier M., Staszewski L.M., and Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain Cell 78 1994 787 798
11. Xirodimas D., Saville M.K., Edling C., Lane D.P., and Lain S. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo Oncogene 20 2001 4972 4983
12. Yabuki N., Watanabe S., Kudoh T., Nihira S., and Miyamato C. Application of homogeneous time-resolved fluorescence (HTRFTM) to monitor poly-ubiquitination of wild-type p53 Comb. Chem. High Throughput Screen 2 1999 279 287